Our in vivo experiments demonstrated that nivolumab inhibited lung metastasis of osteosarcoma rather than primary tumor growth by increasing the numbers of CD4+ and CD8+ lymphocytes as well as cytolytic activity of CD8 lymphocytes in the lung. Here, CD4 is linked to neoplasm.